How is science combating #coronavirus? Learn about the 3 step approach to beating the virus. #COVID19 1/5
— Novartis (@Novartis) May 26, 2020
At Novartis, we want to make a positive impact on the environment and have set ourselves ambitious targets for carbon, water and plastic neutrality. #aRaceWeCanWin https://t.co/84InKcfbt1
— Novartis (@Novartis) August 26, 2020
Watch on Bloomberg as @VasNarasimhan shares insights on the importance of collaboration during COVID-19. https://t.co/t54sjcpo1H
— Novartis (@Novartis) August 14, 2020
"Antimicrobial resistance is an incredibly important challenge that continues to create tremendous strain for healthcare systems” – @VasNarasimhan. We're proud to be part of the new @AMRActionFund launched today. https://t.co/lHSZHswSrP
— Novartis (@Novartis) July 9, 2020
Meet Paul Aliu. During the pandemic, his team has simplified and sped up processes, while handling a 50% increase in requests from physicians and external researchers to test our existing and investigational medicines against #COVID19. #coronavirus
— Novartis (@Novartis) June 23, 2020
Cell & Gene therapies are changing how we think of medicine. Here’s a look at what they are and how they work. #genetherapy #celltherapy pic.twitter.com/DFY8E24a4N
— Novartis (@Novartis) May 20, 2020
Rigorous, science-led investigation is crucial as we seek solutions to the #coronavirus. #COVID19
— Novartis (@Novartis) May 13, 2020
Meet Florencia, a physician-scientist focused on infectious diseases. Florencia’s bringing her expertise to the fight against #COVID19, designing a large-scale trial to test the effectiveness of a potential treatment. #coronavirus
— Novartis (@Novartis) May 13, 2020
This is his second coronavirus outbreak. And he’s helping lead a new global task force where we’re taking a patient-centric approach. Meet Gervais. https://t.co/IbzG72Ktbr
— Novartis (@Novartis) May 12, 2020
IRC’s work to mitigate the spread of #COVID19 in East Africa’s most vulnerable communities is crucial. Thank you for continuing this important work to support vulnerable communities. https://t.co/6qsBAewhG2
— Novartis (@Novartis) May 8, 2020
We’re working to overcome the challenges of #COVID19 and keep our trials on track and participants in treatment. 1/4
— Novartis (@Novartis) April 30, 2020
The 2009 launch of the first pediatric antimalarial has contributed to a reduction in malaria deaths among children. Yet, today a child still dies of malaria every 2 min. Together we need to continue the fight against malaria. #NovartisGlobalHealth #WorldMalariaDay #MalariaFuture
— Novartis (@Novartis) April 25, 2020
Learn how Advanced Accelerator Applications is using #NuclearMedicine to treat diseases like #Cancer.
— Novartis (@Novartis) February 3, 2020
We’re committed to educating about the impact of #sicklecell disease. To learn about the global burden, hear from a team of experts as they discuss findings from a new survey. https://t.co/O9wThPJmOW pic.twitter.com/QcIZLfkuLV
— Novartis (@Novartis) December 9, 2019
Our purpose is to discover and develop the next generation of breakthrough treatments and reimagine medicine for patients. #ReimaginingMedicine pic.twitter.com/unfK8VieP6
— Novartis (@Novartis) December 5, 2019
Our goal for data & digital in R&D: improved success rates, shortened timelines & breakthrough treatments to patients faster. #ReimaginingMedicine pic.twitter.com/wnMOUp6X4Z
— Novartis (@Novartis) December 4, 2019
Did you know, in the time it has taken you to view this video, someone has been hospitalized for heart failure?
Heart failure is a leading cause of hospitalizations – but it doesn’t have to be. Learn why here: https://t.co/nffA2fZ4cp
— Novartis (@Novartis) November 15, 2019
Learn how @Novartis is ensuring medicine supply to leprosy and malaria patients during #COVID19 https://t.co/LjTABED6GD #MalariaFuture #zeroleprosy #NovartisGlobalHealth
— Novartis Global Health (@NovartisGH) August 7, 2020
1/ "From my earliest childhood memories growing up near Lake Victoria, we were accustomed to malaria and the resulting fatalities. It was a common disease and we were oblivious that this shouldn't have been the case."- @RaceyMuchilwa #takeoverweek #WorldMosquitoDay #MalariaFuture pic.twitter.com/xft6GgFZii
— Novartis Global Health (@NovartisGH) August 26, 2020
All choices above are correct. Learn more about mosquito-borne diseases: https://t.co/u3F5F7lxhj
— Novartis Global Health (@NovartisGH) August 24, 2020
Can India win its fight against malaria? Dr. PL Joshi of @MalariaNoMore and
Dr. Pankaj Patil of @Novartis_NSB discuss progress and challenges
ahead: https://t.co/bDurRS6igj #MalariaFuture #WorldMalariaReport #endmalaria @TimesNow— Novartis Global Health (@NovartisGH) January 17, 2020
"The health and care system that we reorient today toward smarter technology will be the one that saves lives tomorrow.” In light of #COVID19, our @AnnAertsNF discusses increasing digital preparedness of health care systems on @MorningConsult. Read more: https://t.co/1DYKviPurF pic.twitter.com/TsjjLjPXrb
— Novartis Foundation (@NovartisFDN) May 4, 2020
#COVID19 isn’t the only disease that’s predominantly found in urban areas. We’ve been at the forefront of urban population health with #BetterHeartsBetterCities, and agree now is the time to build inclusive, resilient & sustainable cities: https://t.co/m8AYTBUQOE
— Novartis Foundation (@NovartisFDN) July 30, 2020
@NovartisFDN partnered with the Government of Ghana on a telemedicine program, where women, like Louisa Akwa, play a crucial role. We believe in sharing stories of women health workers around the globe to help support women in healthcare: https://t.co/Bo7tJntgjz #Dutyofcare https://t.co/xyGViTP6yV
— Novartis Foundation (@NovartisFDN) July 15, 2020
Curious to learn more about @NovartisFDN activities in 2019? Check out the Novartis in Society report which was published today: https://t.co/LtuA3OnPQb pic.twitter.com/Td8dcIgy3f
— Novartis Foundation (@NovartisFDN) January 29, 2020
Our new DASH blog series will take you around the world to hear stories from the ground on how digital health experts have forged ahead in the midst of the pandemic.
Stay tuned for the first installation in the series, launching tomorrow morning at 8 👏https://t.co/6lfk8AvkXE
— HarvardGlobalHealthInstitute (@HarvardGH) July 29, 2020
https://twitter.com/IntHealthAI/status/1296425528648491010
Can image-based #AI meaningfully impact the #COVID19 response in low-resource settings? Join us on June 16 at 15:00 CET for a @DASHglobalAI webinar in partnership with @NovartisFDN, @HarvardGH, @ITU and Grupo Tellus. Register now: https://t.co/Jn8p7L8n2S
— Ann Aerts (@AnnAertsNF) June 12, 2020
I'm excited to share four publications that illustrate how the Communities for Healthy Hearts program in Vietnam raised awareness of hypertension and strengthened the primary care system @NovartisFDN @PATHtweets #talkingNCDs #NovartisGlobalHealthhttps://t.co/btbJPvdiqU
— Ann Aerts (@AnnAertsNF) June 2, 2020
“We’re going to eliminate the oldest disease we know with the newest technology we have available.” @AnnAertsNF@NovartisFDN and @Microsoft are working together to help eliminate leprosy: https://t.co/d1R3xNu0ik pic.twitter.com/zRQISKSwE7
— Microsoft Europe (@MSEurope) January 15, 2020
Great report showing COVID19 as the catalyst to a healthcare ‘brain-train’, redirecting tech talent towards healing the world, not ruling the world. 72% of tech pros now more likely to join the space than 6 months ago. #PowerfulPairing #ReimagineMedicine https://t.co/BtjA8sgUcz
— Bertrand Bodson (@bbod) June 24, 2020
Dr. Vas Narasimhan, CEO of Novartis, in conversation with Stephanie Mehta. Watch the full video from #FCDavosDialogues here: https://t.co/iQaW32djpa #HCLatDavos Presented by @HCLTech pic.twitter.com/FVyupPs4fG
— Fast Company (@FastCompany) January 22, 2020
#Reading and listening widely helps me keep perspective, and I get a lot of questions about what's on my list. First up is Range, by @DavidEpstein—a #book that explores the power of generalists in a specialized world. Look out for more recommendations in the future. pic.twitter.com/m2mPuTNd63
— Vas Narasimhan (@VasNarasimhan) July 6, 2020
#COVID19 has brought some of the health challenges of our time to the fore. I recently spoke with @WIRED’s @StevenLevy and shared my perspective on some of the ways forward for the industry and the world.#coronavirus https://t.co/4CWlsptf9n
— Vas Narasimhan (@VasNarasimhan) July 3, 2020
On many fronts, #COVID19 has accelerated the #digital revolution in health. Looking forward to speaking later today at @CollisionHQ with @serwer on the challenges and opportunities ahead. You can tune in here: https://t.co/B6wAf6ADNx @Novartis
— Vas Narasimhan (@VasNarasimhan) June 24, 2020
Crisis is a #leadership pressure cooker. There’s been recent debate about how to lead through uncertainty, so I wanted to share a discussion I had w/ my coach @jgberger about what I’m learning in this moment. If you like the clip, here’s the longer video: https://t.co/EFQd06fgNm pic.twitter.com/v1AtK616a9
— Vas Narasimhan (@VasNarasimhan) May 29, 2020
As the pandemic progresses, so do our global response and science-based understanding of #COVID19. Thanks for having me @Monocle24, enjoyed the conversation about the latest global shifts and the ways data and tech are driving us forward. #coronavirus #scienceandtechnology https://t.co/HbPvD2KvBm
— Vas Narasimhan (@VasNarasimhan) May 11, 2020
Our first shipments of #hydroxychloroquine are underway to @HHSGov to support clinical studies evaluating its effectiveness in patients with #COVID19. https://t.co/JrGCZfGSj7
— Vas Narasimhan (@VasNarasimhan) March 30, 2020
11 years ago I helped lead efforts to find a vaccine during the H1N1 pandemic, and it reshaped how I view humanity—as a public health physician, a scientist, and a father. I wanted to share my perspective as we tackle COVID-19. #COVID19 https://t.co/8cGlX45ZNr
— Vas Narasimhan (@VasNarasimhan) March 18, 2020
We are dealing with an extraordinary public health crisis that’s hitting our communities in unprecedented ways and requires an incredible level of collaboration to tackle. @Novartis is taking more steps to help respond to the enormous challenge. @gatesfoundation @IMI_JU #COVID19 https://t.co/eQXpj9wTgc
— Vas Narasimhan (@VasNarasimhan) March 17, 2020
Can we make drug development and manufacturing more sustainable? Excited to collaborate with @AstraZeneca and other partners on tackling this challenge. #NovartisNews https://t.co/QH4mZJnjv8
— Novartis News (@NovartisNews) September 1, 2020
Novartis presents new pooled Phase III data from ORION-10 and -11 at #ESCCongress in patients with atherosclerotic #cardiovascular disease (ASCVD) #NovartisNews
— Novartis News (@NovartisNews) August 30, 2020
Novartis presents new Phase II data at #EBMT20Virtual in patients with paroxysmal nocturnal hemoglobinuria (PNH) #NovartisNews
— Novartis News (@NovartisNews) August 29, 2020
Novartis announces that Phase III ASCEMBL chronic myeloid leukemia trial with novel investigational STAMP inhibitor meets primary endpoint. #CML #NovartisNews
— Novartis News (@NovartisNews) August 26, 2020
Novartis provides update on Phase III study evaluating therapy to treat advanced melanoma. #NovartisNews
— Novartis News (@NovartisNews) August 22, 2020
Novartis receives FDA approval for the first and only targeted #Bcell #MultipleSclerosis therapy that is self-administered at home via an autoinjector pen for treatment of patients with relapsing forms of MS (RMS) #NovartisNews #ReimaginingMedicine
— Novartis News (@NovartisNews) August 20, 2020
Novartis receives EC approval for new treatment for severe chronic rhinosinusitis with nasal polyps. #NovartisNews
— Novartis News (@NovartisNews) August 6, 2020
Novartis announces journal publication of Phase III ASCLEPIOS trials in @NEJM regarding impact on disease activity and disability progression in patients with Relapsing #MultipleSclerosis (RMS). #Neuroscience #NovartisNews #ReimaginingMedicine
— Novartis News (@NovartisNews) August 6, 2020
Pivotal CAR-T follicular lymphoma study meets primary endpoint of complete response rate at interim analysis #CARTCellStory #NovartisNews
— Novartis News (@NovartisNews) August 4, 2020
#Breaking: AveXis is now @NovartisGene. Learn more: https://t.co/av0C3H72As pic.twitter.com/eaeerEZBZW
— Novartis Gene Therapies (@NovartisGene) September 2, 2020
Early intervention is crucial to diagnosing and treating #SpinalMuscularAtrophy (SMA) in newborns. Watch this video to hear families discuss why newborn screening is so important. #SMAAwarenessMonth pic.twitter.com/eQOBiaUmTn
— Novartis Gene Therapies (@NovartisGene) August 11, 2020
We’re happy to see Washington state adopt and implement newborn screening for #SpinalMuscularAtrophy (SMA), an important milestone to celebrate during #SMAAwarenessMonth. Learn more at @CureSMA’s website: https://t.co/yVabFeuvy5 pic.twitter.com/ObDH66Kc6U
— Novartis Gene Therapies (@NovartisGene) August 7, 2020
Though microscopic in size, the cells play a huge role in #genetherapy. Curious to learn how? Visit: https://t.co/1M7dEDHVeN pic.twitter.com/WACRdOnVIf
— Novartis Gene Therapies (@NovartisGene) August 7, 2020
#NIH & @FNIH_Org are bringing together 16+ pharma companies & gov’t agencies to develop a national strategy for a coordinated research response to #COVID19 pandemic to speed vaccine and treatment options. #ACTIV https://t.co/g6pilEWiRt pic.twitter.com/QRHEa6BdCg
— NIH (@NIH) April 17, 2020
At @Novartis, fighting #COVID19 on two fronts | #NJBIZ speaks w/ the company's U.S. country head, Thomas Kendris, about its response to the pandemic: "We’re making our medicines available, it’s working out. … I think our people have really stepped up." https://t.co/Fy7yDKcGPk
— NJBIZ (@NJBIZ) April 16, 2020
Novartis is committed to supporting communities, ensuring access to medicines and contributing to research efforts. Learn more at: https://t.co/T0KHj0mxmm pic.twitter.com/SIaTWqLdSK
— Novartis US (@NovartisUS) May 27, 2020
Novartis US Foundation partners w/ @NJPCA to implement telehealth programs at 5 NJ health centers, helping maintain continuity in care during #COVID19 pandemic #NovartisNews Learn more here: https://t.co/Cfp261YwPf pic.twitter.com/0lLmDvirX8
— Novartis US (@NovartisUS) April 30, 2020
Congrats to our associate Lynn McGregor who was named as one of C&EN's 2020 Talented 12 and is a rising star in the #drugdiscovery field! https://t.co/JKqgkyjdzq
— Novartis US (@NovartisUS) August 17, 2020
In these times, it is vital that patients maintain access to critical medications. Thank you to Carol Lynch, President Sandoz US, for these insightful words on the importance of a reliable and resilient supply chain. https://t.co/4nW4x4KLHd
— Novartis US (@NovartisUS) August 14, 2020
At Novartis, we strive to #reimaginemedicine. Check out this interview with @Ameet_Mallik, EVP & Head of US Novartis Oncology, to read about how we are making treatments even more accessible to patients and changing the oncology landscape. https://t.co/mguXt7BygZ
— Novartis US (@NovartisUS) August 3, 2020
We’re honored to have been selected by @GalienFdn as a nominee for the 2020 Best Pharmaceutical Agent. At Novartis, we are committed to innovation and #reimaginingmedicine, and we appreciate all of our associates who work diligently to make this possible. https://t.co/ER4XO56izN
— Novartis US (@NovartisUS) July 22, 2020
Sandoz is collaborating with @CivicaRx to supply critical injectable generic medicines to help reduce supply shortages and ensure acute care settings are able to deliver optimal patient care. #NovartisNews https://t.co/Uc9bCSQ4va pic.twitter.com/k0IrCdn8f2
— Novartis US (@NovartisUS) July 8, 2020
40 community organizations received grants through the Novartis US Foundation COVID-19 Community Response Fund established in April to support COVID-19 response and recovery efforts related to the pandemic. Learn more about these organizations: https://t.co/e8subvhRXA pic.twitter.com/BXaGGdXQXw
— Novartis US (@NovartisUS) June 30, 2020
Check out the June issue of @PharmExec to read about the Novartis US Foundation’s support for local initiatives and communities in the US impacted by COVID-19 https://t.co/4kzNDPQ5uu https://t.co/DA7ZNXnNzb
— Novartis US (@NovartisUS) June 16, 2020
At Novartis, we have no tolerance for racism or bias of any kind. We stand together to help stop the spread of racism, hatred and violence. Read more from our CEO here: https://t.co/gzVcTKUxoD
— Novartis US (@NovartisUS) June 2, 2020
Thank you @VasNarasimhan for sharing these valuable insights. We’re all in this together as we fight against COVID-19.@NYSE https://t.co/dGQ72mI9O0
— Novartis US (@NovartisUS) May 8, 2020
We are dedicated to working to find solutions to the COVID-19 pandemic. Together we can make a difference. https://t.co/48Bq62TNo7
— Novartis US (@NovartisUS) May 8, 2020
Proud to support the @AscendLeader COVID-19 Action Agenda https://t.co/W8LNtMD34g
— Novartis US (@NovartisUS) May 2, 2020